Shetty Ravi Dyavar, Ph.D.

Research Assistant ProfessorDr. Dyavar

Department of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
986145 Nebraska Medical Center
Omaha, NE 68198-6145
402-559-2716 (Lab)
Email

Research Activities/Interests:
Dr. Dyavar’s research projects are focused on developing effective combination antiretroviral therapies (cART) to limit human immunodeficiency virus (HIV) replication in lymphatic tissues with the goal of clearing HIV reservoirs in infected patients. He has several collaborative projects ranging from identifying novel drug-drug interactions during HIV-TB combination therapies; finding the novel molecular targets to develop novel therapies to treat Parkinson’s disease; pharmacokinetic and pharmacogenomics analysis of rifamycin antibiotics and rifamycin-efavirenz combination therapies to identify the role of drug transporters and drug metabolizing enzymes to develop effective TB and HIV-TB combination therapies.

Recent Publications:

  1. Dyavar SR*, Ye Z, Byrareddy SN, Scarsi KK, Winchester LC, Weinhold JA, Fletcher CV, Podany AT. Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay. Scientific Reports. 2018 Feb 26;8(1):3626. doi: 10.1038/s41598-018-21882-0.
  2. Podany AT, Bares SH, Havens J, Dyavar SR, O'neill J, Lee S, Fletcher CV, Swindells S, Scarsi KK. Plasma and Intracellular Pharmacokinetics of Tenofovir in Patients Switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.  AIDS. 2018. doi: 10.1097/QAD.0000000000001744.
  3. Dyavar SR, A. Podany, N. Gautam, Winchester, T. Mykris, J. Weinhold, K. Campbell, Y. Alnouti, C. Fletcher. Assessing antiretroviral drug (ARV) bioavailability in HIV tissue reservoirs using in vitro and in vivo pharmacokinetic (PK) studies with human primary lymphoid endothelial cells and mice. Journal of Virus Eradication. 2017. 3 (Suppl 5):17
  4. Dyavar SR*, Velu V. Early Initiation of Antiretroviral Therapy Decreases the Risk of AIDS and Non-AIDS related mortalities and promotes CD4 T cell recovery during Asymptomatic HIV infection. Pharma Healthcare. 2015. 1:100102.
  5. Velu V, Dyavar SR, Larsson M and Esaki MR. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology. 2015. 2:14. doi: 10.1186/s12977-015-0144-x
  6. Dyavar SR, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, and Amara RR. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. Journal of Clinical Investigation. 2012. 122(17): 1712-1716.
  7. Dyavar SR. In vivo PD-1 blockade enhances leukocyte extravasation and antiviral gene expression in SIV infected Rhesus macaques. 2010. AIDS Research Human Retroviruses. 26 (Suppl 10): A82.
  8. Kulkarni A, Dyavar SR, Singh K, Rampalli S, Parekh V, Mitra D, and Chattopadhyay S. HIV-1 Tat modulates T-bet expression and induces Th1 type of immune response. Biochemistry Biophysics Research Communication. 2005. 329(2):706-712.
  9. Salunke DBϮ, Dyavar SR Ϯ, Pore VS, Mitra D, and Hazra BG. Amino functionalized novel cholic acid derivatives induce HIV-1 replication and syncytia formation in T cells. Journal of Medicinal Chemistry. 2006. 49(8):2652-2655.
  10. Dyavar SR, and Mitra D. HIV-1 long terminal repeat promoter regulated dual reporter: potential use in screening of transcription modulators. Analytical Biochemistry. 2007. 360(2):315-317.

* Corresponding author

Ϯ Equal contribution with the first author